P\u0113d\u0113jos gados Ozempic (semaglutids) ir k\u013cuvis popul\u0101rs medikaments 2. tipa cukura diab\u0113ta \u0101rst\u0113\u0161anai. S\u0101kotn\u0113ji izstr\u0101d\u0101ts k\u0101 medikaments diab\u0113ta \u0101rst\u0113\u0161anai, t\u0101 ietekme uz svara samazin\u0101\u0161anos ir guvusi iev\u0113r\u012bbu, k\u0101 rezult\u0101t\u0101 to arvien bie\u017e\u0101k lieto svara kontrolei cilv\u0113kiem bez diab\u0113ta. T\u0101pat k\u0101 lietojot jebkuru medikamentozu \u0101rst\u0113\u0161anu, ir svar\u012bgi izprast iesp\u0113jam\u0101s blakuspar\u0101d\u012bbas, kas saist\u012btas ar t\u0101 lieto\u0161anu, jo \u012bpa\u0161i saist\u012bb\u0101 ar svara samazin\u0101\u0161anu.<\/p>\n
\u0160aj\u0101 rakst\u0101 m\u0113s apspried\u012bsim jaun\u0101kos p\u0113t\u012bjumus par Ozempic blakuspar\u0101d\u012bb\u0101m, k\u0101 tas pal\u012bdz zaud\u0113t svaru un ilgtermi\u0146a dro\u0161\u012bbas apsv\u0113rumus tiem, kas lieto \u0161o z\u0101\u013cu. Izp\u0113tot bie\u017e\u0101k sastopam\u0101s un nopietn\u0101s blakuspar\u0101d\u012bbas, m\u0113s varam lab\u0101k izprast t\u0101s visp\u0101r\u0113jo ietekmi uz vesel\u012bbu un pal\u012bdz\u0113t cilv\u0113kiem pie\u0146emt inform\u0113tus l\u0113mumus par t\u0101s lieto\u0161anu.<\/p>\n
Ozempic ir tirdzniec\u012bbas nosaukums semaglutids<\/strong>, glikagonam l\u012bdz\u012bga pept\u012bda-1 (GLP-1) receptoru agonists. S\u0101kotn\u0113ji izstr\u0101d\u0101ts un 2017. gad\u0101 apstiprin\u0101ts ASV P\u0101rtikas un z\u0101\u013cu administr\u0101cijas (FDA) 2. tipa cukura diab\u0113ta \u0101rst\u0113\u0161anai, Ozempic kop\u0161 t\u0101 laika ir guvis pla\u0161u iev\u0113r\u012bbu, pateicoties t\u0101 efektivit\u0101tei svara samazin\u0101\u0161anas veicin\u0101\u0161an\u0101.<\/p>\n Ozempic (semaglutids) ir ieguvis iev\u0113rojamu popularit\u0101ti vair\u0101ku iemeslu d\u0113\u013c, jo \u012bpa\u0161i t\u0101 efektivit\u0101tes d\u0113\u013c 2. tipa diab\u0113ta \u0101rst\u0113\u0161an\u0101 un t\u0101 pieaugo\u0161\u0101s izmanto\u0161anas svara samazin\u0101\u0161anai. L\u016bk, k\u0101p\u0113c tas ir k\u013cuvis tik labi zin\u0101ms:<\/p>\n Ozempic ir injic\u0113jamas z\u0101les, kas pal\u012bdz pazemin\u0101t cukura l\u012bmeni asin\u012bs cilv\u0113kiem ar 2. tipa diab\u0113tu.<\/p>\n Viens no svar\u012bg\u0101kajiem t\u0101 popularit\u0101tes iemesliem, \u012bpa\u0161i cilv\u0113kiem bez diab\u0113ta, ir t\u0101 sp\u0113ja veicin\u0101t svara zudumu. Kl\u012bniskie p\u0113t\u012bjumi liecina, ka Ozempic var izrais\u012bt iev\u0113rojamu svara samazin\u0101\u0161anos pat cilv\u0113kiem, kuriem nav diab\u0113ta.<\/p>\n At\u0161\u0137ir\u012bb\u0101 no daudziem citiem diab\u0113ta medikamentiem, kurus nepiecie\u0161ams lietot katru dienu, Ozempic tiek injic\u0113ts vienu reizi ned\u0113\u013c\u0101, t\u0101d\u0113j\u0101di uzlabojot \u0113rt\u012bbas un \u0101rst\u0113\u0161anas iev\u0113ro\u0161anu. Tas ir \u012bpa\u0161i pievilc\u012bgi cilv\u0113kiem, kuri v\u0113las, lai medikamentu lieto\u0161anas grafiks b\u016btu viegl\u0101k kontrol\u0113jams.<\/p>\n Par Ozempic ir daudz run\u0101ts pla\u0161sazi\u0146as l\u012bdzek\u013cos un soci\u0101lajos medijos, jo \u012bpa\u0161i ar influenceriem un slaven\u012bb\u0101m, kas piemin t\u0101 priek\u0161roc\u012bbas. Daudzi lietot\u0101ji dal\u012bj\u0101s ar saviem pan\u0101kumiem svara samazin\u0101\u0161anas jom\u0101, kas veicin\u0101ja t\u0101 k\u0101 svara samazin\u0101\u0161anas l\u012bdzek\u013ca pieaugo\u0161o popularit\u0101ti. \u0160is \"slaven\u012bbu apstiprin\u0101jums\" ir pievienojis soci\u0101l\u0101 apstiprin\u0101juma sl\u0101ni, t\u0101d\u0113j\u0101di palielinot cilv\u0113ku interesi izm\u0113\u0123in\u0101t \u0161o produktu.<\/p>\n Pasaul\u0113 pieaugot aptauko\u0161an\u0101s r\u0101d\u012bt\u0101jiem, arvien vair\u0101k cilv\u0113ku mekl\u0113 veidus, k\u0101 kontrol\u0113t vai zaud\u0113t svaru. Ozempic k\u0101 sal\u012bdzino\u0161i jauns l\u012bdzeklis svara samazin\u0101\u0161anas z\u0101\u013cu arsen\u0101l\u0101 k\u013c\u016bst arvien popul\u0101r\u0101ks, jo pieaug izpratne par aptauko\u0161anos k\u0101 hronisku slim\u012bbu, kurai nepiecie\u0161ama ilgtermi\u0146a \u0101rst\u0113\u0161ana.<\/p>\n Daudzi kl\u012bniskie p\u0113t\u012bjumi ir pier\u0101d\u012bju\u0161i Ozempic efektivit\u0101ti gan 2. tipa diab\u0113ta \u0101rst\u0113\u0161an\u0101, gan svara samazin\u0101\u0161an\u0101. T\u0101 p\u0101rliecino\u0161ie kl\u012bniskie dati, kas apstiprina \u0161\u012bs priek\u0161roc\u012bbas, ir veicin\u0101ju\u0161i pla\u0161u vesel\u012bbas apr\u016bpes pakalpojumu sniedz\u0113ju ievie\u0161anu.<\/p>\n Daudziem cilv\u0113kiem ir gr\u016bti zaud\u0113t svaru tikai ar di\u0113tu un fizisk\u0101m aktivit\u0101t\u0113m. Ozempic pied\u0101v\u0101 alternat\u012bvu pieeju svara samazin\u0101\u0161anai, jo \u012bpa\u0161i cilv\u0113kiem ar lieko svaru vai aptauko\u0161anos, kuri ir sask\u0101ru\u0161ies ar cit\u0101m metod\u0113m.<\/p>\n T\u0101 k\u0101 arvien vair\u0101k \u0101rstu izraksta Ozempic un ir papla\u0161in\u0101jies z\u0101\u013cu apdro\u0161in\u0101\u0161anas segums, t\u0101s ir k\u013cuvu\u0161as pieejam\u0101kas pla\u0161\u0101kam cilv\u0113ku lokam, kas v\u0113l vair\u0101k palielina to popularit\u0101ti.<\/p>\n Ozempic efektivit\u0101te, lieto\u0161anas vieglums (injekcija reizi ned\u0113\u013c\u0101) un relat\u012bvi zem\u0101ks nopietnu blakuspar\u0101d\u012bbu risks sal\u012bdzin\u0101jum\u0101 ar citiem svara samazin\u0101\u0161anas vai diab\u0113ta medikamentiem padara to par pievilc\u012bgu izv\u0113li daudziem pacientiem.<\/p>\n Tas darbojas, imit\u0113jot dab\u0101 sastopam\u0101 hormona, ko sauc par hormonu, darb\u012bbu. glikagonam l\u012bdz\u012bgais pept\u012bds-1 (GLP-1)<\/strong>), kam ir vair\u0101kas svar\u012bgas lomas cukura l\u012bme\u0146a asin\u012bs un apet\u012btes regul\u0113\u0161an\u0101. Ozempic darb\u012bbas meh\u0101nismu var iedal\u012bt vair\u0101kos galvenajos efektos:<\/p>\n <\/p>\n <\/p>\n Neskatoties uz daudzsolo\u0161o ietekmi uz svara kontroli, Ozempic nav bez riska. Izpratne par iesp\u0113jam\u0101m blakuspar\u0101d\u012bb\u0101m ir b\u016btiska tiem, kuri apsver iesp\u0113ju lietot \u0161o z\u0101\u013cu k\u0101 da\u013cu no svara samazin\u0101\u0161anas strat\u0113\u0123ijas.<\/p>\n Lai gan ir pier\u0101d\u012bts, ka semaglutids ir efekt\u012bvs svara samazin\u0101\u0161anas l\u012bdzeklis, ir zi\u0146ots par vair\u0101k\u0101m bie\u017ei sastopam\u0101m blakuspar\u0101d\u012bb\u0101m, \u012bpa\u0161i \u0101rst\u0113\u0161anas s\u0101kumposm\u0101. \u0160\u012bs blakuspar\u0101d\u012bbas bie\u017ei vien ir saist\u012btas ar ku\u0146\u0123a un zarnu trakta (KZT) sist\u0113mu, kas ir bie\u017ea probl\u0113ma daudziem GLP-1 receptoru agonistiem.<\/p>\n Ozempic lieto\u0161anas laik\u0101 visbie\u017e\u0101k zi\u0146ots par blakuspar\u0101d\u012bb\u0101m ku\u0146\u0123a-zarnu trakt\u0101. \u0160\u012bs blakuspar\u0101d\u012bbas var b\u016bt no viegl\u0101m l\u012bdz smag\u0101m, un laika gait\u0101 t\u0101m ir tendence mazin\u0101ties, jo organisms piel\u0101gojas z\u0101\u013cu iedarb\u012bbai.<\/p>\n Slikta d\u016b\u0161a ir visbie\u017e\u0101k sastopam\u0101 blakuspar\u0101d\u012bba, kas saist\u012bta ar Ozempic lieto\u0161anu. Kl\u012bniskajos p\u0113t\u012bjumos ku\u0146\u0123a-zarnu trakta blakuspar\u0101d\u012bbas bija vienas no visbie\u017e\u0101k zi\u0146otaj\u0101m, \u012bpa\u0161i devas palielin\u0101\u0161anas f\u0101z\u0113. Piem\u0113ram, Wegovy (semaglutids, ko lieto svara samazin\u0101\u0161anai) STEP p\u0113t\u012bjum\u0101 slikta d\u016b\u0161a rad\u0101s 27,8% dal\u012bbniekiem (1).<\/p>\n Slikta d\u016b\u0161a parasti rodas, kad organisms piel\u0101gojas z\u0101l\u0113m, un bie\u017ei vien t\u0101 ir vissmag\u0101k\u0101, kad devu palielina.<\/p>\n K\u0101p\u0113c tas notiek:<\/strong> Slikta d\u016b\u0161a rodas t\u0101p\u0113c, ka semaglutids pal\u0113nina ku\u0146\u0123a iztuk\u0161o\u0161anos, kas var izrais\u012bt pilnuma un diskomforta saj\u016btu. Turkl\u0101t sliktu d\u016b\u0161u saj\u016btu var veicin\u0101t ar\u012b GLP-1 receptoru aktiv\u0101cija smadzen\u0113s.<\/p>\n Pas\u0101kumu norise:<\/strong> Daudziem pacientiem slikta d\u016b\u0161a izz\u016bd da\u017eu ned\u0113\u013cu laik\u0101, jo organisms pierod pie z\u0101\u013cu lieto\u0161anas. S\u0101kot ar maz\u0101ku devu un pak\u0101peniski palielinot devu, var pal\u012bdz\u0113t mazin\u0101t sliktu d\u016b\u0161u. Ja slikta d\u016b\u0161a saglab\u0101jas, var b\u016bt nepiecie\u0161ams samazin\u0101t devu vai p\u0101riet uz alternat\u012bvu \u0101rst\u0113\u0161anu.<\/p>\n Vem\u0161ana ir v\u0113l viena iesp\u0113jama blakuspar\u0101d\u012bba, lai gan t\u0101 ir ret\u0101ka nek\u0101 slikta d\u016b\u0161a. P\u0113t\u012bjumi liecina, ka vem\u0161ana rodas nelielai da\u013cai pacientu, parasti kop\u0101 ar citiem ku\u0146\u0123a-zarnu trakta simptomiem.<\/p>\n Semaglutids var trauc\u0113t ku\u0146\u0123a un zarnu trakta motoriku, izraisot gan caureju, gan aizciet\u0113jumus da\u017eiem lietot\u0101jiem. Caureja ir bie\u017e\u0101k sastopama \u0101rst\u0113\u0161anas s\u0101kumposm\u0101, un bie\u017ei vien to var nov\u0113rst, piel\u0101gojot di\u0113tu vai medikamentus simptomu kontrolei.<\/p>\n No otras puses, aizciet\u0113jums var k\u013c\u016bt par probl\u0113mu da\u017eiem lietot\u0101jiem, kuriem z\u0101\u013cu lieto\u0161anas d\u0113\u013c samazin\u0101s ku\u0146\u0123a un zarnu trakta motorika. Lai mazin\u0101tu aizciet\u0113jumus, bie\u017ei vien tiek ieteikta pietiekama hidrat\u0101cija un \u0161\u0137iedrvielu lieto\u0161ana uztur\u0101.<\/p>\n Da\u017eiem lietot\u0101jiem var rasties s\u0101pes v\u0113der\u0101 vai diskomforts. Parasti t\u0101s ir vieglas un var b\u016bt saist\u012btas ar pal\u0113nin\u0101tu ku\u0146\u0123a iztuk\u0161o\u0161anos vai z\u0101\u013cu izrais\u012bt\u0101m ku\u0146\u0123a-zarnu trakta darb\u012bbas izmai\u0146\u0101m.<\/p>\n Viena no galvenaj\u0101m Ozempic iedarb\u012bb\u0101m ir t\u0101 sp\u0113ja nom\u0101kt apet\u012bti, kas veicina svara zudumu. \u0160is efekts parasti ir labv\u0113l\u012bgs tiem, kuri v\u0113las zaud\u0113t svaru, bet da\u017ek\u0101rt var izrais\u012bt samazin\u0101tu interesi par \u0113dienu, kas retos gad\u012bjumos var izrais\u012bt nepietiekamu uzturu vai nepietiekamu uzturu.<\/p>\n Apet\u012bta izmai\u0146u p\u0101rvald\u012bba:<\/strong> Ir svar\u012bgi, lai cilv\u0113ki, kuri lieto Ozempic svara samazin\u0101\u0161anai, p\u0101rliecin\u0101tos, ka vi\u0146i lieto pareiz\u0101s uzturvielas, \u012bpa\u0161i, ja apet\u012bte ir iev\u0113rojami samazin\u0101jusies. Uztura konsult\u0101cijas vai sadarb\u012bba ar dietologu var pal\u012bdz\u0113t nodro\u0161in\u0101t, ka svara zudums tiek pan\u0101kts vesel\u012bgi un ilgtsp\u0113j\u012bgi.<\/p>\n Lai gan hipoglik\u0113mija (zems cukura l\u012bmenis asin\u012bs) bie\u017e\u0101k ir saist\u012bta ar t\u0101d\u0101m pretdiab\u0113ta z\u0101l\u0113m k\u0101 insul\u012bns vai sulfonilur\u012bnvielas atvasin\u0101jumi, t\u0101 var rasties ar\u012b cilv\u0113kiem, kuri lieto Ozempic, \u012bpa\u0161i kombin\u0101cij\u0101 ar cit\u0101m cukura l\u012bmeni asin\u012bs pazemino\u0161\u0101m z\u0101l\u0113m (3).<\/p>\n Hipoglik\u0113mijas simptomi:<\/strong> Simptomi ir tr\u012bce, reibonis, apjukums, sv\u012b\u0161ana un izsalkums. Smagos gad\u012bjumos hipoglik\u0113mija var izrais\u012bt krampjus vai bezsama\u0146u.<\/p>\n Riska faktori:<\/strong> Hipoglik\u0113mijas risks ir liel\u0101ks pacientiem, kuri lieto ar\u012b citas diab\u0113ta z\u0101les, \u012bpa\u0161i insul\u012bnu vai sulfonilur\u012bnvielas atvasin\u0101jumus. Tom\u0113r, ja tos lieto atsevi\u0161\u0137i \u0137erme\u0146a masas samazin\u0101\u0161anai, hipoglik\u0113mijas risks parasti ir zems.<\/p>\n Ozempic ievada ar zem\u0101das injekciju, parasti reizi ned\u0113\u013c\u0101. Da\u017eiem cilv\u0113kiem injekcijas viet\u0101 var rasties kairin\u0101jums, tostarp aps\u0101rtums, piet\u016bkums vai nieze (4). \u0160\u012bs reakcijas parasti ir vieglas un spont\u0101ni izz\u016bd da\u017eu stundu vai dienu laik\u0101.<\/p>\n Nesenie p\u0113t\u012bjumi liecina, ka svara atg\u016b\u0161ana p\u0113c Ozempic lieto\u0161anas p\u0101rtrauk\u0161anas ir izplat\u012bta probl\u0113ma, kas saist\u012bta ar z\u0101\u013cu apet\u012bti nom\u0101co\u0161\u0101s un metabolisk\u0101s iedarb\u012bbas p\u0101rtrauk\u0161anu (5).<\/p>\n P\u0113t\u012bjumi liecina, ka p\u0113c z\u0101\u013cu lieto\u0161anas p\u0101rtrauk\u0161anas var atg\u016bt aptuveni 30-50% no zaud\u0113t\u0101 svara, t\u0101d\u0113j\u0101di uzsverot nepiecie\u0161am\u012bbu ilgtermi\u0146\u0101 main\u012bt dz\u012bvesveidu, lai saglab\u0101tu svara zudumu.<\/p>\n Lai samazin\u0101tu atk\u0101rtotu svara pieaugumu, ir svar\u012bgi, lai pacienti iev\u0113rotu sabalans\u0113tu uzturu, regul\u0101ri veiktu fizisk\u0101s aktivit\u0101tes un vajadz\u012bbas gad\u012bjum\u0101 sa\u0146emtu psiholo\u0123isku atbalstu. Cie\u0161a sadarb\u012bba ar vesel\u012bbas apr\u016bpes speci\u0101listiem ir \u013coti svar\u012bga, lai izstr\u0101d\u0101tu ilgtsp\u0113j\u012bgu svara kontroles pl\u0101nu p\u0113c Ozempic atcel\u0161anas.<\/p>\n Lai gan vairums Ozempic blakuspar\u0101d\u012bbu ir vieglas un kontrol\u0113jamas, ir da\u017ei nopietn\u0101ki riski, par kuriem pacientiem b\u016btu j\u0101zina.<\/p>\n Viena no liel\u0101kaj\u0101m ba\u017e\u0101m, kas saist\u012bta ar Ozempic lieto\u0161anu, ir pankreat\u012bta iesp\u0113jam\u012bba (6). Pankreat\u012bts ir reta, bet nopietna slim\u012bba, kas var izrais\u012bt stipras s\u0101pes v\u0113der\u0101, vem\u0161anu un citas komplik\u0101cijas.<\/p>\n Riska faktori:<\/strong> Pacientiem ar pankreat\u012btu vai cit\u0101m aizku\u0146\u0123a dziedzera slim\u012bb\u0101m anamn\u0113z\u0113 var b\u016bt paaugstin\u0101ts risks. Turkl\u0101t pacientiem ar \u017eultsakme\u0146iem vai pacientiem, kuri lieto lielu alkohola daudzumu, var b\u016bt liel\u0101ka nosliece uz pankreat\u012bta att\u012bst\u012bbu.<\/p>\n Pas\u0101kumu norise:<\/strong> Ja rodas pankreat\u012bta simptomi (stipras s\u0101pes v\u0113der\u0101, vem\u0161ana, drudzis u. c.), nekav\u0113joties j\u0101p\u0101rtrauc Ozempic lieto\u0161ana un j\u0101mekl\u0113 \u0101rsta pal\u012bdz\u012bba.<\/p>\n P\u0113t\u012bjumos ar dz\u012bvniekiem ir pier\u0101d\u012bts, ka semaglutids palielina vairogdziedzera \u013caundab\u012bgo audz\u0113ju, tostarp medul\u0101ras vairogdziedzera karcinomas (MTC), kas ir reta un agres\u012bva v\u0113\u017ea forma, risku (7). Lai gan risks cilv\u0113kiem nav prec\u012bzi noteikts, Ozempic z\u0101\u013cu aprakst\u0101 ir iek\u013cauts br\u012bdin\u0101jums par \u0161o iesp\u0113jamo risku.<\/p>\n Iemesls<\/strong>: Z\u0101\u013cu darb\u012bbas meh\u0101nisms, kas saist\u012bts ar GLP-1 receptoru aktiviz\u0113\u0161anu, var ietekm\u0113t vairogdziedzera \u0161\u016bnas grauz\u0113jiem, lai gan nav konstat\u0113ti ar to saist\u012bti gad\u012bjumi cilv\u0113kiem.<\/p>\n Pas\u0101kumu norise:<\/strong> Ozempic ir kontrindic\u0113ts cilv\u0113kiem, kuriem person\u012bgi vai \u0123imenes anamn\u0113z\u0113 ir medul\u0101rais vairogdziedzera v\u0113zis, vai cilv\u0113kiem ar 2. tipa multiplo endokr\u012bno neopl\u0101ziju (MEN 2), retu \u0123en\u0113tisku trauc\u0113jumu, kas palielina vairogdziedzera v\u0113\u017ea risku.<\/p>\n Ir sa\u0146emti zi\u0146ojumi par nieru darb\u012bbas trauc\u0113jumiem, tostarp ak\u016btu nieru boj\u0101jumu, da\u017eiem cilv\u0113kiem, kuri lietoju\u0161i Ozempic, \u012bpa\u0161i tiem, kuriem bijusi stipra slikta d\u016b\u0161a un vem\u0161ana, kas izrais\u012bjusi dehidrat\u0101ciju (8). Nieru probl\u0113mas ir bie\u017e\u0101k iesp\u0113jamas cilv\u0113kiem ar jau eso\u0161\u0101m nieru slim\u012bb\u0101m vai tiem, kam ir gr\u016bt\u012bbas uztur\u0113t pietiekamu hidrat\u0101ciju.<\/p>\n Iemesls<\/strong>: Dehidrat\u0101cija, ko izraisa ku\u0146\u0123a un zarnu trakta blakuspar\u0101d\u012bbas (piem\u0113ram, vem\u0161ana un caureja), var veicin\u0101t nieru slodzi.<\/p>\n Pas\u0101kumu norise:<\/strong> Pacienti j\u0101nov\u0113ro, vai nepar\u0101d\u0101s nieru darb\u012bbas trauc\u0113jumu paz\u012bmes, jo \u012bpa\u0161i, ja vi\u0146iem ir past\u0101v\u012bgi ku\u0146\u0123a-zarnu trakta simptomi vai dehidrat\u0101cija. Lai mazin\u0101tu nieru komplik\u0101ciju risku, ir svar\u012bgi nodro\u0161in\u0101t pietiekamu \u0161\u0137idruma uz\u0146em\u0161anu.<\/p>\n Ozempic lieto\u0161ana ir saist\u012bta ar paaugstin\u0101tu \u017eultsp\u016b\u0161\u013ca slim\u012bbu, tostarp \u017eultsakme\u0146u, risku. \u017dultsakme\u0146i var izrais\u012bt stipras s\u0101pes v\u0113der\u0101 un var b\u016bt nepiecie\u0161ama \u0137irur\u0123iska iejauk\u0161an\u0101s.<\/p>\n Pas\u0101kumu norise:<\/strong> Ozempic lietot\u0101jiem j\u0101uzman\u0101s no t\u0101diem simptomiem k\u0101 stipras s\u0101pes v\u0113der\u0101, slikta d\u016b\u0161a un vem\u0161ana, kas var liecin\u0101t par \u017eultsp\u016b\u0161\u013ca probl\u0113m\u0101m. Ja \u0161\u0101di simptomi rodas, nekav\u0113joties j\u0101konsult\u0113jas ar \u0101rstu.<\/p>\n Da\u017ei pier\u0101d\u012bjumi liecina, ka GLP-1 receptoru agonisti, piem\u0113ram, Ozempic, var palielin\u0101t diab\u0113tisk\u0101s retinop\u0101tijas risku cilv\u0113kiem ar jau eso\u0161u diab\u0113tu. Tom\u0113r pier\u0101d\u012bjumi par \u0161o saikni nav p\u0101rliecino\u0161i, un ir nepiecie\u0161ami papildu p\u0113t\u012bjumi, lai izprastu semaglutida ilgtermi\u0146a ietekmi uz acu vesel\u012bbu.<\/p>\n Da\u017eiem pacientiem, kuri lieto semaglutidus, nov\u0113rota neliela sirdsdarb\u012bbas pa\u0101trin\u0101\u0161an\u0101s, lai gan \u0161\u012bs par\u0101d\u012bbas kl\u012bnisk\u0101 noz\u012bme v\u0113l tiek p\u0113t\u012bta (9).<\/p>\n Iemesls<\/strong>: Z\u0101\u013cu iedarb\u012bba uz ve\u0123etat\u012bvo nervu sist\u0113mu var izrais\u012bt nelielu sirdsdarb\u012bbas pa\u0101trin\u0101\u0161anos.<\/p>\n \u00a0<\/strong><\/p>\n Daudzas ar Ozempic lieto\u0161anu saist\u012bt\u0101s ku\u0146\u0123a-zarnu trakta blakuspar\u0101d\u012bbas, piem\u0113ram, slikta d\u016b\u0161a un vem\u0161ana, parasti izz\u016bd, kad organisms pierod pie z\u0101\u013cu lieto\u0161anas. Tom\u0113r da\u017eiem pacientiem \u0161\u012bs blakuspar\u0101d\u012bbas var saglab\u0101ties, kas var ietekm\u0113t \u0101rst\u0113\u0161anas iev\u0113ro\u0161anu.<\/p>\n Jaunos p\u0113t\u012bjumos tiek p\u0113t\u012bta semaglutida lieto\u0161anas iesp\u0113jam\u0101 psiholo\u0123isk\u0101 ietekme. Da\u017ei cilv\u0113ki zi\u0146o, ka, lietojot GLP-1 receptoru agonistus, nov\u0113ro garast\u0101vok\u013ca sv\u0101rst\u012bbas vai depresijas simptomus, lai gan \u0161\u012bs blakuspar\u0101d\u012bbas ir retas (10). Nepiecie\u0161ami turpm\u0101ki p\u0113t\u012bjumi, lai nov\u0113rt\u0113tu Ozempic ilgtermi\u0146a psiholo\u0123isko ietekmi, jo \u012bpa\u0161i pacientiem, kuri z\u0101les lieto svara samazin\u0101\u0161anai, nevis diab\u0113ta \u0101rst\u0113\u0161anai.<\/p>\n Pamatojums<\/strong>: GLP-1 receptoru agonistiem, piem\u0113ram, semaglutidam, ir ietekme uz centr\u0101lo nervu sist\u0113mu, kas jut\u012bgiem cilv\u0113kiem var ietekm\u0113t garast\u0101vokli.<\/p>\n M\u016bsupr\u0101t, semaglutida blakuspar\u0101d\u012bbu skaits, piem\u0113ram, iesp\u0113jam\u0101 depresijas, ozempiskas sejas vai ku\u0146\u0123a-zarnu trakta darb\u012bbas trauc\u0113jumu izrais\u012b\u0161ana un jo-jo efekts p\u0113c lieto\u0161anas p\u0101rtrauk\u0161anas, ir p\u0101r\u0101k liels, lai ieteiktu \u0161o z\u0101\u013cu lieto\u0161anu ikvienam, kas v\u0113las zaud\u0113t da\u017eus kilogramus.<\/p>\n Svara zudums ir gr\u016bts process, un ir dabiski, ka cilv\u0113ki mekl\u0113 atbalsta metodes.<\/p>\n Pamats ir pareizi sabalans\u0113t uzturu un pl\u0101not fizisk\u0101s aktivit\u0101tes. Lai b\u016btu veseli, tas ir neizb\u0113gami.<\/p>\n Ja ir nepiecie\u0161ama atbalsto\u0161u vielu lieto\u0161ana, tad viens no dro\u0161\u0101kiem un efekt\u012bv\u0101kiem risin\u0101jumiem b\u016bs uzlabot mitohondriju funkciju, izmantojot. Metil\u0113nzils<\/a> i NMN<\/a>. Tas \u013caus m\u016bsu \u0137ermenim ra\u017eot vair\u0101k ener\u0123ijas, t\u0101p\u0113c m\u0113s b\u016bsim mobil\u0101ki un mums b\u016bs daudz viegl\u0101k uzs\u0101kt vingrin\u0101jumus. Ja m\u0113s pl\u0101nojam, piem\u0113ram, tr\u012bs treni\u0146us ned\u0113\u013c\u0101, m\u0113s var\u0113sim tren\u0113ties ilg\u0101k un intens\u012bv\u0101k un sadedzin\u0101t vair\u0101k kaloriju ar vair\u0101k ener\u0123ijas.<\/p>\n Ja tas izr\u0101d\u0101s nepietiekams, tad j\u016bs var\u0113tu apsv\u0113rt iesp\u0113ju lietot CJC 1295 bez DAC ar Impamorelinu, lai palielin\u0101tu dabisk\u0101 aug\u0161anas hormona izvadi. Augst\u0101ks aug\u0161anas hormona l\u012bmenis \u013cauj daudz viegl\u0101k sadedzin\u0101t taukus. Turkl\u0101t augst\u0101ks aug\u0161anas hormona l\u012bmenis pa\u0101trina atvese\u013co\u0161anos, uzlabo miegu un \u0101das kvalit\u0101ti.<\/p>\n \u0160is raksts ir rakst\u012bts izgl\u012btojo\u0161iem nol\u016bkiem, un t\u0101 m\u0113r\u0137is ir veicin\u0101t izpratni par apl\u016bkojamo vielu. Ir svar\u012bgi atz\u012bm\u0113t, ka raksts ir par vielu kopum\u0101 - tas nav konkr\u0113ta produkta (\u0137\u012bmisk\u0101 rea\u0123enta) apraksts. M\u0113s neiesak\u0101m lietot \u0137\u012bmiskos rea\u0123entus uz cilv\u0113kiem - tas ir aizliegts ar likumu. Lai produktu var\u0113tu izmantot \u0101rst\u0113\u0161anai, tam j\u0101b\u016bt re\u0123istr\u0113tam k\u0101 z\u0101l\u0113m. Tekst\u0101 ietvert\u0101 inform\u0101cija ir balst\u012bta uz pieejamajiem zin\u0101tniskajiem p\u0113t\u012bjumiem, un t\u0101 nav paredz\u0113ta k\u0101 medic\u012bnisks padoms vai pa\u0161\u0101rst\u0113\u0161an\u0101s veicin\u0101\u0161anai. Las\u012bt\u0101jam par visiem vesel\u012bbas un \u0101rst\u0113\u0161anas l\u0113mumiem j\u0101konsult\u0113jas ar kvalific\u0113tu vesel\u012bbas apr\u016bpes speci\u0101listu.<\/p>\n P\u0113d\u0113jos gados Ozempic (semaglut\u012bds) ir k\u013cuvis par popul\u0101ru 2. tipa cukura diab\u0113ta \u0101rst\u0113\u0161anas l\u012bdzekli. S\u0101kotn\u0113ji tas tika izstr\u0101d\u0101ts k\u0101 z\u0101les diab\u0113ta \u0101rst\u0113\u0161anai, un t\u0101 ietekme uz svara zudumu\u2026<\/p>","protected":false},"author":7908,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-25983","post","type-post","status-publish","format-standard","hentry","category-bez-kategorii","beh-no-thumb"],"_links":{"self":[{"href":"https:\/\/bioevidencehub.com\/lv\/wp-json\/wp\/v2\/posts\/25983","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bioevidencehub.com\/lv\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bioevidencehub.com\/lv\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bioevidencehub.com\/lv\/wp-json\/wp\/v2\/users\/7908"}],"replies":[{"embeddable":true,"href":"https:\/\/bioevidencehub.com\/lv\/wp-json\/wp\/v2\/comments?post=25983"}],"version-history":[{"count":0,"href":"https:\/\/bioevidencehub.com\/lv\/wp-json\/wp\/v2\/posts\/25983\/revisions"}],"wp:attachment":[{"href":"https:\/\/bioevidencehub.com\/lv\/wp-json\/wp\/v2\/media?parent=25983"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bioevidencehub.com\/lv\/wp-json\/wp\/v2\/categories?post=25983"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bioevidencehub.com\/lv\/wp-json\/wp\/v2\/tags?post=25983"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}K\u0101p\u0113c Ozempic ir popul\u0101rs?<\/h2>\n
\n
Efekt\u012bva 2. tipa diab\u0113ta \u0101rst\u0113\u0161ana<\/h3>\n<\/li>\n<\/ol>\n
\n
\n
Svara zuduma priek\u0161roc\u012bbas<\/h3>\n<\/li>\n<\/ol>\n
\n
\n
Devu lieto reizi ned\u0113\u013c\u0101<\/h3>\n<\/li>\n<\/ol>\n
\n
Pan\u0101kumu st\u0101sti un soci\u0101lo mediju a\u017eiot\u0101\u017ea<\/h4>\n<\/li>\n<\/ol>\n
\n
Liel\u0101ka inform\u0113t\u012bba par aptauko\u0161anos<\/h3>\n<\/li>\n<\/ol>\n
\n
P\u0113tniec\u012bba un efektivit\u0101te<\/h3>\n<\/li>\n<\/ol>\n
\n
Alternat\u012bva tradicion\u0101laj\u0101m svara zaud\u0113\u0161anas metod\u0113m<\/h3>\n<\/li>\n<\/ol>\n
\n
Tirgus papla\u0161in\u0101\u0161an\u0101s<\/h3>\n<\/li>\n<\/ol>\n
\n
Sal\u012bdzin\u0101jums ar cit\u0101m z\u0101l\u0113m<\/h3>\n<\/li>\n<\/ol>\n
Darb\u012bbas meh\u0101nisms:<\/h2>\n
\n
In insul\u012bna sekr\u0113cijas stimul\u0113\u0161ana<\/h3>\n<\/li>\n<\/ol>\n
\n
\n
Glikagona sekr\u0113cijas inhib\u012bcija<\/h3>\n<\/li>\n<\/ol>\n
\n
\n
Ku\u0146\u0123a iztuk\u0161o\u0161an\u0101s aizkav\u0113\u0161ana<\/h3>\n<\/li>\n<\/ol>\n
\n
\n
Apet\u012bta samazin\u0101\u0161an\u0101s<\/h3>\n<\/li>\n<\/ol>\n
\n
\n
Beta \u0161\u016bnu funkcijas uzlabo\u0161ana<\/h3>\n<\/li>\n<\/ol>\n
\n
\n
Sirds un asinsvadu sist\u0113mas darb\u012bbas rezult\u0101tu uzlabo\u0161ana<\/h3>\n<\/li>\n<\/ol>\n
\n
K\u0101 Ozempic veicina svara zudumu<\/h2>\n
\n
Apet\u012bta nom\u0101k\u0161ana<\/h3>\n<\/li>\n<\/ol>\n
\n
\n
L\u0113n\u0101ka ku\u0146\u0123a iztuk\u0161o\u0161an\u0101s<\/h3>\n<\/li>\n<\/ol>\n
\n
\n
Paaugstin\u0101ta jut\u012bba pret insul\u012bnu<\/h3>\n<\/li>\n<\/ol>\n
\n
\n
Tauku metabolisma modul\u0101cija<\/h3>\n<\/li>\n<\/ol>\n
\n
\n
Liel\u0101ks svara zudums kl\u012bniskajos p\u0113t\u012bjumos<\/h3>\n<\/li>\n<\/ol>\n
\n
\u00a0Kl\u012bniskie p\u0113t\u012bjumi, kas apstiprina svara zudumu:<\/h2>\n
\n
\n
Bie\u017ei sastopam\u0101s Ozempic blakuspar\u0101d\u012bbas<\/h2>\n
\n
Ku\u0146\u0123a un zarnu trakta probl\u0113mas<\/h3>\n<\/li>\n<\/ol>\n
\n
Slikta d\u016b\u0161a<\/h3>\n<\/li>\n<\/ul>\n
\n
\n
\n
\n
Apet\u012bta nom\u0101k\u0161ana un svara zudums<\/h3>\n<\/li>\n<\/ol>\n
\n
Hipoglik\u0113mija (zems cukura l\u012bmenis asin\u012bs)<\/h3>\n<\/li>\n<\/ol>\n
\n
Reakcijas injekcijas viet\u0101<\/h3>\n<\/li>\n<\/ol>\n
\n
Svara pieaugums p\u0113c Ozempic lieto\u0161anas p\u0101rtrauk\u0161anas<\/h3>\n<\/li>\n<\/ol>\n
Nopietnas Ozempic blakuspar\u0101d\u012bbas<\/h2>\n
\n
Pankreat\u012bts<\/h3>\n<\/li>\n<\/ol>\n
\n
Vairogdziedzera audz\u0113ji (medul\u0101r\u0101 vairogdziedzera karcinoma)<\/h3>\n<\/li>\n<\/ol>\n
\n
Nieru probl\u0113mas<\/h3>\n<\/li>\n<\/ol>\n
\n
\u017dultsp\u016b\u0161\u013ca slim\u012bba<\/h3>\n<\/li>\n<\/ol>\n
\n
Retinop\u0101tija<\/h3>\n<\/li>\n<\/ol>\n
\n
Paaugstin\u0101ts sirdsdarb\u012bbas \u0101trums<\/h3>\n<\/li>\n<\/ol>\n
Ilgtermi\u0146a apsv\u0113rumi un jauni p\u0113t\u012bjumi<\/h2>\n
Tolerance pret blakuspar\u0101d\u012bb\u0101m<\/h3>\n
Psihisk\u0101s vesel\u012bbas ietekmes p\u0113t\u012bjums<\/h3>\n
Vai ir dro\u0161\u0101kas alternat\u012bvas?<\/h2>\n
Atruna<\/h2>\n
Atsauces<\/h2>\n
\n